EP. 3: Understanding and Mitigating the Cardiometabolic Risks of ADTApril 14th 2023
Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
EP. 4: Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?April 14th 2023
Dr Higano provides a timeline review of safety results for GnH agonists and GnRH antagonists including the recent prospective phase 3 PRONOUNCE study for prostate cancer patients with pre-existing CV disease, followed by closing thoughts on this video series.